CCL2 is considered a prognostic indicator for AML, as elevated CCL2 levels in untreated AML patients were associated with poor cytogenetic profiles and, thus, with an unfavorable prognosis [98,99,100]. This evidence concerns the gene CCL2 and acute myeloid leukemia.